188 related articles for article (PubMed ID: 22256846)
21. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
22. Accidental anthracycline extravasation.
Held-Warmkessel J
Nursing; 2007 Dec; 37(12 Pt.1):72. PubMed ID: 18090648
[No Abstract] [Full Text] [Related]
23. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
Arroyo PA; Perez RU; Feijoo MA; Hernandez MA
J Cancer Res Ther; 2010; 6(4):573-4. PubMed ID: 21358106
[TBL] [Abstract][Full Text] [Related]
24. Management of anthracycline extravasation injuries.
Reeves D
Ann Pharmacother; 2007 Jul; 41(7):1238-42. PubMed ID: 17550954
[TBL] [Abstract][Full Text] [Related]
25. Dexrazoxane in anthracycline extravasation.
Langer SW; Sehested M; Jensen PB; Buter J; Giaccone G
J Clin Oncol; 2000 Aug; 18(16):3064. PubMed ID: 10944144
[No Abstract] [Full Text] [Related]
26. Dexrazoxane use in the prevention of anthracycline extravasation injury.
Hasinoff BB
Future Oncol; 2006 Feb; 2(1):15-20. PubMed ID: 16556068
[TBL] [Abstract][Full Text] [Related]
27. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
28. Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.
Caballero Romero Á; Delgado Ureña MT; Salmerón García A; Megías Fernández MT; Librada Porriño-Bustamante M; Cabeza Barrera J
Anticancer Drugs; 2018 Oct; 29(9):821-826. PubMed ID: 30036190
[TBL] [Abstract][Full Text] [Related]
29. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.
Mouridsen HT; Langer SW; Buter J; Eidtmann H; Rosti G; de Wit M; Knoblauch P; Rasmussen A; Dahlstrøm K; Jensen PB; Giaccone G
Ann Oncol; 2007 Mar; 18(3):546-50. PubMed ID: 17185744
[TBL] [Abstract][Full Text] [Related]
30. Dexrazoxane treatment for intrathoracic anthracycline extravasation.
Schulmeister L
Onkologie; 2008 Nov; 31(11):634. PubMed ID: 19145099
[No Abstract] [Full Text] [Related]
31. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
Langer SW; Sehested M; Jensen PB
Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
[TBL] [Abstract][Full Text] [Related]
32. Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.
Jensen JN; Lock-Andersen J; Langer SW; Mejer J
Scand J Plast Reconstr Surg Hand Surg; 2003; 37(3):174-5. PubMed ID: 12841619
[TBL] [Abstract][Full Text] [Related]
33. Clinical nurse specialist and evidence-based practice: managing anthracycline extravasation.
Hooke MC
J Pediatr Oncol Nurs; 2005; 22(5):261-4. PubMed ID: 16079361
[TBL] [Abstract][Full Text] [Related]
34. Re: Totect: a new agent for treating anthracycline extravasation.
Ward MS
Clin J Oncol Nurs; 2007 Oct; 11(5):613; author reply 613. PubMed ID: 17962168
[No Abstract] [Full Text] [Related]
35. Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion.
Comas D; Mateu J
Ann Pharmacother; 1996 Mar; 30(3):244-6. PubMed ID: 8833558
[TBL] [Abstract][Full Text] [Related]
36. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
37. Delayed presentation of doxorubicin extravasation into pleural space: Case report and review of literature.
Kazakova V; Vanegas YAM; Torres TA; Kozyreva O
J Oncol Pharm Pract; 2021 Sep; 27(6):1520-1527. PubMed ID: 33241731
[TBL] [Abstract][Full Text] [Related]
38. Extravasation management.
Schulmeister L
Semin Oncol Nurs; 2007 Aug; 23(3):184-90. PubMed ID: 17693345
[TBL] [Abstract][Full Text] [Related]
39. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Silber JH
Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
[No Abstract] [Full Text] [Related]
40. Savene® (dexrazoxane) use in clinical practice.
Fontaine C; Noens L; Pierre P; De Grève J
Support Care Cancer; 2012 May; 20(5):1109-12. PubMed ID: 22278308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
